# A Study to Learn About mRNA Vaccines Against Influenza in Adults

> **NCT07431853** · PHASE2 · RECRUITING · sponsor: **Pfizer** · enrollment: 770 (estimated)

## Conditions studied

- Healthy Adults

## Interventions

- **BIOLOGICAL:** Vaccine Candidate #1
- **BIOLOGICAL:** Vaccine Candidate #2
- **BIOLOGICAL:** Vaccine Candidate #3
- **BIOLOGICAL:** Vaccine Candidate #4
- **BIOLOGICAL:** Vaccine Candidate #5
- **BIOLOGICAL:** Vaccine Candidate #6
- **BIOLOGICAL:** TIV1 or TIV2

## Key facts

- **NCT ID:** NCT07431853
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-23
- **Primary completion:** 2027-06-22
- **Final completion:** 2027-06-22
- **Target enrollment:** 770 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07431853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07431853, "A Study to Learn About mRNA Vaccines Against Influenza in Adults". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07431853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*